C Bucci-Rechtweg
Overview
Explore the profile of C Bucci-Rechtweg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Johnson T, Sahin L, Tassinari M, Anderson P, Baker T, et al.
Clin Pharmacol Ther
. 2017 May;
101(6):736-744.
PMID: 28510297
This report serves as a summary of a 2-day public workshop sponsored by the US Food and Drug Administration (FDA) to discuss the safety of drugs and biological products used...
2.
Reid I, Black D, Eastell R, Bucci-Rechtweg C, Su G, Hue T, et al.
J Clin Endocrinol Metab
. 2013 Jan;
98(2):557-63.
PMID: 23293335
Context: Annual infusions of zoledronic acid 5 mg over 3 years have been shown to reduce fracture incidence. There is now evidence that the effects of a single dose of...
3.
Roux C, Reid D, Devogelaer J, Saag K, Lau C, Reginster J, et al.
Osteoporos Int
. 2011 Oct;
23(3):1083-90.
PMID: 21975559
This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate...
4.
Wustrack R, Seeman E, Bucci-Rechtweg C, Burch S, Palermo L, Black D
Osteoporos Int
. 2011 Jun;
23(1):53-8.
PMID: 21691843
Unlabelled: We examined prevalent and recent vertebral fractures in 1 year as predictors of new vertebral fractures over subsequent 2 years using data from RCT placebo patients. We found that...
5.
Adachi J, Lyles K, Colon-Emeric C, Boonen S, Pieper C, Mautalen C, et al.
Osteoporos Int
. 2011 Jan;
22(9):2539-49.
PMID: 21249332
Unlabelled: This study evaluated the benefits of ZOL versus placebo on health-related quality of life (HRQoL) among patients from HORIZON-RFT. At month 24 and end of the study visit, ZOL...
6.
Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, et al.
Osteoporos Int
. 2010 Dec;
22(8):2329-36.
PMID: 21153021
Unlabelled: Patients in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Recurrent Fracture Trial were assessed for evidence of delayed hip fracture healing. No association was...